$ANVS

Annovis Bio (ANVS) aims for March 2027 readout in Alzheimer's trial, focusing on p-tau217-positive subgroup. The company plans an NDA submission if six-month data meets efficacy criteria, but needs $15M by year-end to fund operations. CEO also discussed Parkinson's disease studies and regulatory plans. Annovis has $19M in cash, expecting to burn $7M-$9M monthly.

Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results · Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. · Parkinson’s disease (PD) open-label extension (OLE)

Annovis Bio (NYSE: ANVS) reported Q2 2026 results and business updates. Its pivotal Phase 3 early Alzheimer’s trial is fully enrolled with 850 patients (target 760). The AD open-label extension is planned for Oct 2026, and the Parkinson’s OLE has 266 enrolled. Cash was $18.7M at June 30, 2026; Q2 net loss was $0.40/share.

Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001477845 0001477845 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report

Annovis Bio (NYSE: ANVS) said the NYSE has confirmed it regained full compliance with continued listing standards. The NYSE notified the company on March 26, 2025 for failing Section 802.01B after average market cap and stockholders’ equity fell below $50 million for 30 days. Annovis’ plan was accepted June 19, 2025 with an 18-month cure period; compliance was restored within 12 months.

Annovis Bio (ANVS) is seeking stockholder approval at its virtual 2026 Annual Meeting on June 17, 2026, to expand its 2019 Equity Incentive Plan. The proposed amendment would increase the total share reserve from 4,000,000 to 5,500,000 shares and raise the maximum individual annual grant limit from 400,000 to 600,000 shares. Stockholders will also vote on other matters, including the election of directors, ratification of Ernst & Young LLP as auditor, and advisory proposals on executive compensation and its frequency.

Annovis Bio (ANVS) has announced a registered direct offering of 5.26 million shares of common stock, combined with warrants to purchase an equal number of additional shares, at a price of $1.90 per unit. The offering is expected to generate approximately $9.175 million in net proceeds, which the company plans to allocate towards the continued Phase 3 clinical development of its lead compound, buntanetap, for Alzheimer's disease, as well as for general working capital and corporate needs. Post-offering, the outstanding shares are projected to be around 34.53 million, highlighting a dilution for existing shareholders.

This page provides news and events for ANVS.N, Annovis Bio, including recent corporate announcements, financial reports, and study updates. Key highlights include a partnership with NeuroRPM for Parkinson's disease monitoring, the company's cash and cash equivalents, and positive safety recommendations for its Phase 3 Alzheimer's trial. The content also lists past news articles and upcoming events related to the company's research and financial performance.

Annovis Bio, Inc. has partnered with NeuroRPM to integrate an FDA-cleared AI platform into its ongoing Phase 3 study for Parkinson's disease. This collaboration will utilize wearable technology to continuously monitor core Parkinson's symptoms in real-world settings, providing comprehensive data on disease progression and treatment response. The study, which also includes a diagnostic biomarker test, aims to gather extensive information for a deeper understanding of Parkinson's disease.

This article examines the hypothetical returns of a $1,000 investment in Annovis Bio Inc (ANVS) over different periods, showcasing significant losses over 5 and 10 years, despite a gain in the last year. It also provides a detailed company overview, highlighting ANVS as a late-stage clinical drug platform company focused on neurodegenerative diseases with its lead drug candidate, buntanetap, in trials for Alzheimer's and Parkinson's. The company's therapeutic strategy, clinical focus, regulatory pathway, and financial profile are discussed.